1. Effect of G6PD Activity, Mediterranean Mutation and Some Biomarkers on Patients with Diabetes Mellitus
- Author
-
Akeel Hussein Al-Aisse, Abdulqader Wael Rasheid, Firas T. Maher, and Adnan Fadhel Nasseef
- Subjects
congenital, hereditary, and neonatal diseases and abnormalities ,medicine.medical_specialty ,business.industry ,nutritional and metabolic diseases ,Blood sugar ,General Medicine ,medicine.disease ,Obesity ,Blood pressure ,Endocrinology ,hemic and lymphatic diseases ,Internal medicine ,Diabetes mellitus ,parasitic diseases ,medicine ,Medical history ,business ,Body mass index ,Dyslipidemia ,Whole blood - Abstract
Diabetes mellitus is a metabolic disease belongs to a group of disparate diseases clinically and genetically characterized by increased blood sugar (hyperglycemia) as a result of defect in insulin metabolism. Glucose-6-Phosphate Dehydrogenase (G6PD) (Oxidoreductase, EC 1.1.1.1-49) is one of the most important enzymes of the metabolite, the main enzyme and the key to the Pentose phosphate path way. Unsuitable control of blood glucose decreases G6PD activity and increases diabetes mellitus complications. the This study evaluated effect of Mediterranean mutation which causes decrease G6PD activity on diabetes patients and evaluated the difference of G6PD activity among diabetic and non-diabetic patients, and the impact of hyperglycemia on the G6PD activity and different in G6PD activity in six and age and relation between Calcium and Magnesium with G6PD activity and Mediterranean mutation and found correlative coefficient(r) between G6PD activity in Patient and Blood sugar, Calcium, Magnesium and G6PD activity in healthy people. Asixteen diabetic and non-diabetic subjects were selected from patients 8 to 60 years old. Demographic data including gender, age, height, weight, duration of diabetes mellitus, type and duration of treatment, medical history (especially fauvism) were recorded. Blood pressure and body mass index were also measured. One blood sample was taken from each subject and 5 elements including G6PD presence and activity, fasting plasma glucose, plasma Calcium, Magnesium and DNA was extraction from whole blood and then amplified by polymerase chain reaction (PCR) and later subjected to digestion by restriction enzyme MboII to create restriction fragment length polymorphism (RFLP) to enable the detection of mutation that caused G6PD deficiency namely Mediterranean (Med). G6PD activity was significantly higher in non-diabetic subjects (P
- Published
- 2021
- Full Text
- View/download PDF